%PDF-1.4
%
35 0 obj
<>
endobj
32 0 obj
<>
endobj
163 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-12-02T14:16:39Z
2024-03-28T04:27:39-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-28T04:27:39-07:00
application/pdf
Heather
201102.nov
uuid:f50f8504-1dd1-11b2-0a00-d80827bd3700
uuid:f50f8507-1dd1-11b2-0a00-5b0000000000
endstream
endobj
21 0 obj
<>
endobj
22 0 obj
<>
endobj
36 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
17 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
180 0 obj
[185 0 R]
endobj
181 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT0 1 Tf
0.1031 Tw 10 0 0 10 54 713.1616 Tm
(group \223other arthritis\224? How can we cope with the confu-)Tj
0.02499 Tw 0 -1.2 TD
(sion that will ensue?)Tj
-0.0061 Tw 1.2 -1.2 Td
(The results of our evaluation imply that with some minor)Tj
0.1678 Tw -1.2 -1.2 Td
(changes in the new classification more children could be)Tj
0.1877 Tw T*
(precisely categorized without losing the claim for homo-)Tj
0.1951 Tw T*
(geneity within the subgroups \227 the primary goal of the)Tj
-0.00011 Tc 0.02499 Tw T*
(ILAR classification and basis for scientific studies.)Tj
/TT1 1 Tf
0 Tc -0.02299 Tw 0 -1.42 TD
[(Suggestions to r)37 (educe the number of patients in the category)]TJ
0.01781 Tw 0 -1.18 TD
[(\223Other arthritis\224 \227 an indefinite category)55 (. )]TJ
/TT0 1 Tf
17.6888 0 Td
(The majority of)Tj
0.0015 Tw -17.6888 -1.18 Td
(our patients in the category \223other arthritis\224 fulfilled criteria)Tj
-0.00011 Tc 0.026 Tw T*
[(for 2 categories \(16 of 27 patients\). )18 (This concerned 1)37 (1 chil-)]TJ
0 Tc -0.00819 Tw T*
(dren with an enthesitis related arthritis who had arthritis and)Tj
0.0132 Tw T*
[(enthesitis. However)40 (, they also fulfilled criteria for RF nega-)]TJ
0.10429 Tw T*
(tive polyarthritis or oligoarthritis. If enthesitis becomes an)Tj
0.09129 Tw T*
(exclusion criterion for RF negative polyarthritis as well as)Tj
0.12061 Tw T*
(for oligoarthritis, these patients could be correctly catego-)Tj
-0.00011 Tc 0.02499 Tw T*
(rized as enthesitis related arthritis.)Tj
0 Tc 0.21201 Tw 1.2 -1.2 Td
(The same principle could be applied to children with)Tj
-0.00011 Tc -0.0327 Tw -1.2 -1.2 Td
(criteria for psoriatic arthritis as well as poly- or oligoarthritis)Tj
0.00639 Tw 0 -1.2 TD
[(\227 5 in our study)65 (. Psoriasis as an exclusion for patients with)]TJ
0 Tc 0.0607 Tw T*
(poly- or oligoarthritis improves classification of these chil-)Tj
0.00349 Tw T*
[(dren. )18 (They would be categorized as psoriatic arthritis. Since)]TJ
-0.0081 Tw T*
(it has been accepted in the ILAR classification that psoriatic)Tj
0.33839 Tw T*
(arthritis will contain a rather inhomogeneous group of)Tj
0.03169 Tw T*
(patients, this step would not interfere with the primary goal)Tj
0.0058 Tw T*
(of the new system. In fact it would leave more patients with)Tj
0.2263 Tw T*
(psoriatic arthritis to be studied, thus helping to improve)Tj
0.31149 Tw T*
[(insight into this category)65 (, which most likely comprises)]TJ
-0.00011 Tc 0.0202 Tw T*
(further subgroups of patients)Tj
0 Tc 0 Tw 6.5 0 0 6.5 169.8404 380.0618 Tm
(8)Tj
0.0202 Tw 10 0 0 10 173.0904 376.7618 Tm
(. Eight of our 27 patients with)Tj
0.3266 Tw -11.909 -1.2 Td
(\223other arthritis\224 had typical oligoarthritis, but a family)Tj
0.0199 Tc 0.4213 Tw T*
(history of psoriasis or HLA-B27 associated disease)Tj
0 Tc 0.2433 Tw T*
[(excluded them from their original category)65 (. )18 (That family)]TJ
-0.036 Tw T*
[(history alone suf)18 (fices to exclude a patient from a category he)]TJ
-0.00011 Tc 0.15421 Tw T*
(or she otherwise would correctly fulfill remains a critical)Tj
-0.0145 Tw T*
(point for further discussion, particularly when one considers)Tj
0 Tc -0.00591 Tw T*
(that the criterion \223psoriasis\224 or \223enthesitis\224 in the indivi\
dual)Tj
0.02499 Tw T*
(patient is not evaluated as strong enough for an exclusion.)Tj
/TT1 1 Tf
-0.00841 Tw 0 -1.42 TD
[(Suggestions for mor)37 (e homogeneity in the category RF nega-)]TJ
0.0081 Tc 0.3669 Tw 0 -1.18 TD
(tive polyarthritis)Tj
/TT0 1 Tf
7.2061 0 Td
[(. )55 (Another aspect that requires further)]TJ
0 Tc 0.1031 Tw -7.2061 -1.18 Td
(discussion concerns the category RF negative polyarthritis)Tj
0.0625 Tw T*
(and its relation to the oligoarticular subgroup. In the ILAR)Tj
0.0728 Tw T*
[(classification only the number of af)18 (fected joints during the)]TJ
-0.00011 Tc 0.0807 Tw T*
[(first 6 months \227 with an arbitrary cutof)18 (f between 4 and 5)]TJ
0 Tc 0.0739 Tw T*
(joints \227 determines the category for an individual patient.)Tj
-0.00011 Tc 0.01511 Tw T*
(This definition is adopted from the former classifications of)Tj
0.1749 Tw T*
[(both the EULAR and the )55 (ACR. However)40 (, we and others)]TJ
0 Tc 0.3634 Tw T*
(have realized that what characterizes the oligoarticular)Tj
0.20731 Tw T*
(subgroup is not the exact number of involved joints but)Tj
0.2753 Tw T*
(rather the asymmetric joint pattern, often with a spotty)Tj
0.04289 Tw T*
(involvement of more than 4 joints)Tj
-0.00011 Tc 0 Tw 6.5 0 0 6.5 191.9509 128.2619 Tm
[(9-1)57 (1)]TJ
0.043 Tw 10 0 0 10 203.4951 124.9619 Tm
[(. )18 (The ILAR classifica-)]TJ
0 Tc 0.0206 Tw -14.9495 -1.18 Td
(tion considers the possibility of extended oligoarthritis with)Tj
0.25349 Tw 26.4 60 Td
(involvement of more than 4 joints, but only during the)Tj
-0.00011 Tc 0.1646 Tw T*
(further course in patients who presented with less than 5)Tj
0 Tc 0.3214 Tw T*
(joints in the first 6 months. Children who develop an)Tj
0.0027 Tc 0.3723 Tw T*
(extended oligoarticular joint pattern within the first 6)Tj
0 Tc 0.0692 Tw T*
[(months have to be categorized as polyarthritis. )18 (This means)]TJ
0.062 Tw T*
(that with the present classification we have to deal with an)Tj
0.0685 Tw T*
(inhomogeneous polyarthritis category \227 with all the unfa-)Tj
-0.00011 Tc 0.35069 Tw T*
(vorable consequences for future studies. Our group of)Tj
0 Tc 0.1188 Tw T*
(patients confirms that 2 major patient populations exist in)Tj
0.0737 Tw T*
[(the category RF negative polyarthritis. )55 (Among the 44 chil-)]TJ
-0.03329 Tw T*
(dren defined as polyarthritis according to the Durban criteria)Tj
0.03391 Tw T*
(only 18 had symmetric polyarthritis of more than 8 big and)Tj
0.1631 Tw T*
[(small joints. )18 (The other 26 children had more in common)]TJ
0.10831 Tw T*
(with the oligoarticular subgroup since they presented with)Tj
0.3224 Tw T*
(an asymmetric pattern of predominantly big joints and)Tj
0.11819 Tw T*
[(showed a high frequency of )55 (ANA, and almost every third)]TJ
0.02499 Tw T*
(patient had chronic uveitis.)Tj
0.0358 Tw 1.2 -1.2 Td
[(W)80 (e therefore strongly suggest introduction of a category)]TJ
0.342 Tw -1.2 -1.2 Td
[(\223extended oligoarthritis at onset.\224 )18 (This subgroup could)]TJ
0.0394 Tw 0 -1.2 TD
(comprise children who present with 5 to 8 joints within the)Tj
0.06171 Tw T*
(first 6 months and who fulfill none of the exclusions listed)Tj
0.0072 Tw T*
[(for the category oligoarthritis. )18 (The cutof)18 (f at 8 joints is again)]TJ
-0.0188 Tw T*
[(arbitrary)65 (, but it improves homogeneity of the patient groups,)]TJ
0.02499 Tw T*
(as we have shown with our data.)Tj
/TT2 1 Tf
-0.00011 Tc 0 Tw 0 -2.4 TD
(REFERENCES)Tj
/TT0 1 Tf
0 Tc 0.02499 Tw 8 0 0 8 325 406.3618 Tm
[(1.)-875 (W)80 (ood PHN. Special meeting on nomenclature and classification of)]TJ
1.675 -1.25 Td
[(arthritis in children. In: Munthe E, editor)55 (. )18 (The care of rheumatic)]TJ
0 -1.25 TD
(children. Basel: EULAR Publishers; 1978:47-50.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(2.)-875 (Brewer EJ, Bass J, Baum J, et al. Current proposed revision of JRA)]TJ
0 Tc 1.675 -1.25 Td
[(criteria. )55 (Arthritis Rheum 1977;20 Suppl:195-9.)]TJ
-1.675 -1.25 Td
[(3.)-875 (Petty RE, Southwood )18 (TR, Baum J, et al. Revision of the proposed)]TJ
1.675 -1.25 Td
(classification criteria for juvenile idiopathic arthritis: Durban 1997.)Tj
T*
(J Rheumatol 1998;25:1991-4.)Tj
-1.675 -1.25 Td
[(4.)-875 (Berntson L. JCA)-220 (in Nordic countries; a population based)]TJ
1.675 -1.25 Td
(multicentre study of construct validity of ILAR, in comparison with)Tj
-0.00011 Tc T*
[(EULAR classification criteria [abstract]. )55 (Ann Rheum Dis)]TJ
0 Tc 0 Tw T*
(2000;59:719.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(5.)-875 (Fantini F)80 (, Gerloni )18 (V)129 (, Gattinara M, )55 (Arnoldi C. Classification of)]TJ
0 Tc 1.675 -1.25 Td
[(juvenile idiopathic arthritis: suggestions to improve the ef)18 (ficacy of)]TJ
-0.00011 Tc T*
[(the Durban criteria [abstract]. )55 (Ann Rheum Dis 2000;59:719.)]TJ
0 Tc -1.675 -1.25 Td
[(6.)-875 (Merino R, De Inocencio J, Garcia-Consuegra J. Evaluation of)]TJ
1.675 -1.25 Td
(Durban classification criteria for juvenile idiopathic arthritis in)Tj
-0.00011 Tc T*
[(Spanish children [abstract]. )55 (Ann Rheum Dis 2000;59:719.)]TJ
-1.675 -1.25 Td
[(7.)-875 (Ramsey SE, Bolaria RK, Cabral DA, Malleson PN, Petty RE.)]TJ
0 Tc 1.675 -1.25 Td
(Comparison of criteria for the classification of childhood arthritis. )Tj
T*
(J Rheumatol 2000;27:1283-6.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(8.)-875 (H\344fner R, Michels H. Psoriatic arthritis in children. Curr Opinion)]TJ
0 Tc 1.675 -1.25 Td
(Rheumatol 1996;8:467-72.)Tj
-1.675 -1.25 Td
[(9.)-875 (Ansell BM. Rheumatic disorders in childhood. London:)]TJ
-0.00011 Tc 1.675 -1.25 Td
(Butterworths; 1980.)Tj
-2.175 -1.25 Td
[(10.)-875 (Michels H, H\344fner R, Morhart R, Schuchmann L, )18 (T)35 (ruckenbrodt H.)]TJ
0 Tc 2.175 -1.25 Td
(Five year follow-up of a prospective cohort of juvenile chronic)Tj
T*
(arthritis with recent onset. Clin Rheumatol 1987;6 Suppl 2:87-92.)Tj
-0.00011 Tc -2.1381 -1.25 Td
[(1)37 (1.)-875 (W)80 (edgwood RJ, Schaller JG. )18 (The pediatric arthritides. Hosp Pract)]TJ
0 Tc 0 Tw 2.1381 -1.25 Td
(1977;84-97.)Tj
ET
0 0 0 0 scn
468 770 90 -25 re
f*
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
0 0 0 1 scn
/TT1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 54.5 35.9844 Tm
[(Krumr)37 (ey-Langkammer)37 (er and H\344fner: JIA)-257 (criteria)]TJ
0 Tc 0 Tw 60.9375 -0.0313 Td
(2547)Tj
ET
Q
Q
q
1 0 0 1 0 -3 cm
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
/CS0 cs 0 0 0 0 scn
101.57 60.89 407.5 -10.84 re
f*
Q
Q
q
1 0 0 1 0 -2 cm
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
/CS0 CS 0 0 0 1 SCN
0.5 w
101.57 60.89 407.5 -10.84 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
ET
/GS2 gs
BT
/T1_0 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2001. All rights reserved.)Tj
ET
Q
BT
0 g
/GS3 gs
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS3 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS3 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
77 0 obj
<>
endobj
169 0 obj
<>
endobj
41 0 obj
<>
endobj
39 0 obj
<>
endobj
48 0 obj
<>
endobj
47 0 obj
<>
endobj
72 0 obj
<>stream
HdVpTs͋lb^(Y#HRY
PCL"]0H2H:#(A^RR<0[
3ZI|!t4U5uosw
@
sdBN%9Ωkl_@떷;JXƖzA u[K`ꦆxs߹ sw
rO{fƭKhh`t-5%ś|Z 7SԲq -Zg}yjB1ljZG=c<S%m;aR~
Q"*լ\>\FtQYhFAL,D7X&0сuͳyX垠^
w >[nGa/5GO1b
"%fr-nD=->8*j8Lb\3蕉n-< ;r3arڪC
x;eUjT=F8~~˪x-F,+zebp+erL'U2jY&O>ӊI)F*jw/wKɤ7e&j\unل[^:lc*#_,ΡC,Ig9-ٕqridYBʍR/wFyX'(/KSNY vm;f~ue51f|e礗yV%Y^ݤUQNHz1Ę`,47ڍnj#0/G-XíVnogfNHL_)4Rޔ'Mj&>i*Y!u;W[kY5NV٣V3yc?ݚ9Q!T>0~r3VVb㛹\q&gwB 4jdxᰂ|C/28A9_40{@VfFzeJP+b~gd1G3fގS'9~*.q1Of?%5C5%?Sw^R;ڈ]wz<~o"~GbS#,f mM>.Z#ۑgG3(wΫF.jŎLor`Ǥ^:ŋuX]oׯ9M1U;FQ1cgqcO>.PCGU:*X53ۘrfժjGV$bOf`G$dacI58[?/m}+XkuJ2ޤxzNp.=3،Li(CG]\dNuo9VQlxJV
4y~"x[Ґ`g3ؙx6[-J+o
Շ=n.9&M`JЛKT9
D KO9zk{r}vaÉ""Hdx@sxFU J@Ig=NgEk흇Sza7[1祚`E)21o6wa=NjWr-:/VX>dz6W˳"wt3/C5m)`
/$*SKn/r8~Tlc\dLDצTV2Ve [u5kk#/.Tp_@i9g{q=ʳizVw
Z"1iiw7.[